Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a systematic review and meta-analysis

Open access
Cai, Changzhou, Song, Xin, Chen, Yishu, Chen, Xueyang, Yu, Chaohui · 2020 · Hepatology International

Abstract

BACKGROUND AND AIM: Nonalcoholic fatty liver disease (NAFLD) has gradually become one of the most common chronic liver diseases in the world. More and more evidence shows that low skeletal muscle mass index (SMI) may play a role in the development of NAFLD. Our aim was to quantify the association between SMI, sarcopenia and the presence and severity of NAFLD. METHODS: We systematically searched English relevant studies from PubMed, Embase, the Web of Science and the Cochrane Library updated to December 20th, 2018. Studies in which SMI was compared between NAFLD cases and controls were included. So were studies concerning the odds ratio (OR) of NAFLD, non-alcoholic steatohepatitis (NASH) and significant fibrosis in sarcopenia patients. Pooled weighted mean differences and ORs were calculated. RESULTS: Of the 1331 retrieved studies, 19 articles were included. SMI level in NAFLD patients was 1.77 (95% CI 1.15, 2.39) lower than that in normal controls. We also found a significantly higher occurrence risk of NAFLD (OR = 1.33, 95% CI 1.20 to 1.48), NASH (OR = 2.42, 95% CI 1.27 to 3.57) and NAFLD-related significant fibrosis (OR = 1.56, 95% CI 1.34, 1.78) in sarcopenia subjects. CONCLUSIONS: SMI level in patients with NAFLD was lower than healthy people, and patients with sarcopenia have higher occurrence risk of NAFLD, as well as its advanced stages including NASH or NAFLD-related significant fibrosis. Further well-designed prospective studies are required to strengthen the arguments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12072-019-09964-1

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flowchart showing the selection of articles included in the meta-analysis
Fig. 1 Flowchart showing the selection of articles included in the meta-analysisCC BY · PubMed Central
Fig. 2 Meta-analysis of skeletal muscle index (SMI) in nonalcoholic fatty liver disease (NAFLD). a A pooled weighted mean difference (WMD) of SMI in overall seven individual studies between NAFLD patients and normal people. b A pooled WMD of SMI in subgroup analysis based on the different SMM measurement methods. c A pooled WMD of SMI in subgroup analysis according to gender. d Sensitivity analysis according to whether the study was in or out of the funnel plot. For each estimate, the grey shaded area is the weight of the estimate in proportion to the overall effect. SMI skeletal muscle index, NAFLD nonalcoholic fatty liver disease, WMD weighted mean difference, NC normal control, SMM skeletal muscle mass, DEXA dual energy X-ray absorptiometry, BIA bioimpedance analysis
Fig. 2 Meta-analysis of skeletal muscle index (SMI) in nonalcoholic fatty liver disease (NAFLD). a A pooled weighted mean difference (WMD) of SMI in overall seven individual studies between NAFLD patients and normal people. b A pooled WMD of SMI in subgroup analysis based on the different SMM measurement methods. c A pooled WMD of SMI in subgroup analysis according to gender. d Sensitivity analysis according to whether the study was in or out of the funnel plot. For each estimate, the grey shaded area is the weight of the estimate in proportion to the overall effect. SMI skeletal muscle index, NAFLD nonalcoholic fatty liver disease, WMD weighted mean difference, NC normal control, SMM skeletal muscle mass, DEXA dual energy X-ray absorptiometry, BIA bioimpedance analysisCC BY · PubMed Central
Fig. 3 Meta-analysis of sarcopenia in nonalcoholic fatty liver disease (NAFLD). a A pooled odds ratio (OR) of NAFLD prevalence between sarcopenia patients and normal control (NC). b Subgroup analysis according to race. c Subgroup analysis based on the sample size. d Sensitivity analysis according to whether the study was in or out of the funnel plot. For each estimate, the grey shaded area is the weight of the estimate in proportion to the overall effect. NAFLD nonalcoholic fatty liver disease, NC normal control, OR odds ratio, HSI hepatic steatosis index, CNS comprehensive NAFLD score, NFS NAFLD fibrosis score, BMI body mass index
Fig. 3 Meta-analysis of sarcopenia in nonalcoholic fatty liver disease (NAFLD). a A pooled odds ratio (OR) of NAFLD prevalence between sarcopenia patients and normal control (NC). b Subgroup analysis according to race. c Subgroup analysis based on the sample size. d Sensitivity analysis according to whether the study was in or out of the funnel plot. For each estimate, the grey shaded area is the weight of the estimate in proportion to the overall effect. NAFLD nonalcoholic fatty liver disease, NC normal control, OR odds ratio, HSI hepatic steatosis index, CNS comprehensive NAFLD score, NFS NAFLD fibrosis score, BMI body mass indexCC BY · PubMed Central
Fig. 4 Meta-analysis of sarcopenia in nonalcoholic fatty liver disease (NAFLD). a A pooled odds ratio (OR) of NAFLD-related significant fibrosis between sarcopenia patients and normal control (NC). b Subgroup analysis according to race. c In NAFLD patients, a pooled OR of NASH between sarcopenia patients and control. d In analyzing the association in patients with sarcopenia and NAFLD-related significant fibrosis. Subgroup analysis was performed based on the diagnostic methods. NAFLD nonalcoholic fatty liver disease, OR: odds ratio, NFS NAFLD fibrosis score, FIB-4 fibrosis index based on the 4 factor, BMI body mass index
Fig. 4 Meta-analysis of sarcopenia in nonalcoholic fatty liver disease (NAFLD). a A pooled odds ratio (OR) of NAFLD-related significant fibrosis between sarcopenia patients and normal control (NC). b Subgroup analysis according to race. c In NAFLD patients, a pooled OR of NASH between sarcopenia patients and control. d In analyzing the association in patients with sarcopenia and NAFLD-related significant fibrosis. Subgroup analysis was performed based on the diagnostic methods. NAFLD nonalcoholic fatty liver disease, OR: odds ratio, NFS NAFLD fibrosis score, FIB-4 fibrosis index based on the 4 factor, BMI body mass indexCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 2

  1. Kwanten WJ, De Fré C, De Fré M, Vonghia L, Vanwolleghem T, Michielsen PP, et al. Sarcopenia is less prevalent in an obese population with NAFLD compared to patients with obesity alone, but increases with severity of disease. Hepatology 2018;68:1282A–1283A
  2. Kim KH, Kim SU. Sarcopenia is independently associated with significant fibrosis as assessed using transient elastography in patients with chronic liver disease. Hepatology 2018;68:1134A · DOI · Paper page

Cited by

See all 127

Metadata

Authors
Cai, C., Song, X., Chen, Y., Chen, X., & Yu, C.
Affiliations
First Affiliated Hospital Zhejiang University (CN)
Corresponding author
Yu, Chaohui
Venue
Hepatology International
Published
2019-07-09
Volume
14
Issue
1
Pages
115-126
ISSN
  • 1936-0533 (ISSN-L)
  • 1936-0541
OpenAlex
W2961155473
Cited by
118
References
33
Citations by year
2026: 12 · 2025: 18 · 2024: 24 · 2023: 12 · 2022: 18 · 2021: 18 · 2020: 14 · 2019: 2
FWCI
1.90
Type
journal article
Language
en
Open access
Licence
Locations
  • Hepatology International (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Key R&D Program of China (2017YFC0908900)
  • National Natural Science Foundation of China (81700485)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Keywords
non-alcoholic fatty liver disease, skeletal muscle index, sarcopenia, nonalcoholic steatohepatitis, liver fibrosis
MeSH terms
Humans, Severity of Illness Index, Muscle, Skeletal, Sarcopenia, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1007/s12072-019-09964-1
The paper
Cai, C., Song, X., Chen, Y., Chen, X., & Yu, C. (2020). Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Hepatology International. https://doi.org/10.1007/s12072-019-09964-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.